• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     European Network for Health Technology Assessment (EUnetHTA) Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia
2021     Health Information and Quality Authority (HIQA) Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) In hospital survival after pancreatoduodenectomy is greater in high volume hospitals versus lower volume hospitals: a meta analysis
2021     National Institute for Health and Care Excellence (NICE) Ofatumumab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 699
2021     National Institute for Health and Care Excellence (NICE) Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids. NICE interventional procedures guidance 704
2021     Ontario Health iStent for Adults With Glaucoma: A Health Technology Assessment
2021     Health Information and Quality Authority (HIQA) Extended interval screening by the Diabetic RetinaScreen Programme in Ireland
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) COVID-19: a test of evidence-based surgery
2021     National Institute for Health and Care Excellence (NICE) Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 700
2021     National Institute for Health and Care Excellence (NICE) Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage. NICE interventional procedures guidance 701
2021     Medical Services Advisory Committee (MSAC) Six genetic tests for the diagnosis of inheritable cardiac conduction disorders
2021     Ontario Health DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines
2021     Health Information and Quality Authority (HIQA) Measures to support people in self-isolation or restriction of movements and the evidence of the effectiveness of such measures
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Evidence, not eminence, for surgical management during COVID-19: a multifaceted systematic review and a model for rapid clinical change
2021     National Institute for Health and Care Excellence (NICE) Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal). NICE technology appraisal guidance 701
2021     National Institute for Health and Care Excellence (NICE) Laser lithotripsy for difficult-to-treat bile duct stones. NICE interventional procedures guidance 699
2021     Ontario Health Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment
2021     Health Information and Quality Authority (HIQA) Potential impact of different serial testing scenarios using rapid antigen detection tests (RADTs) to detect SARS-CoV-2 in meat processing plant workers
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Addendum to Commission A20-102]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular feedback therapy for paraplegia]
2021     National Institute for Health and Care Excellence (NICE) Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal). NICE technology appraisal guidance 702
2021     National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve. NICE interventional procedures guidance 700
2021     European Network for Health Technology Assessment (EUnetHTA) Convalescent plasma therapy for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Analysis of factors associated with outbreaks of SARS-CoV-2 in nursing homes in Ireland
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114]
2021     National Institute for Health and Care Excellence (NICE) Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 703
2021     National Institute for Health and Care Excellence (NICE) Electrohydraulic lithotripsy for difficult-to-treat bile duct stones. NICE interventional procedures guidance 698
2021     Health Information and Quality Authority (HIQA) Potential impact of different testing scenarios and durations of mandatory home quarantine for people travelling to Ireland from non-designated states
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Addendum to Commission A20-113]
2021     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2021     National Institute for Health and Care Excellence (NICE) Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant. NICE interventional procedures guidance 695
2021     European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Public health measures to limit the transmission of SARS-CoV-2 at mass gatherings
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endoscopic thermoablation of the duodenal mucosa in type 2 diabetes - Addendum to commission H20-04]
2021     National Institute for Health and Care Excellence (NICE) Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 705
2021     National Institute for Health and Care Excellence (NICE) Transvaginal laser therapy for stress urinary incontinence. NICE interventional procedures guidance 696
2021     European Network for Health Technology Assessment (EUnetHTA) Camostat for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Duration of immunity (protection from reinfection) following SARS-CoV-2 infection
2021     Malaysian Health Technology Assessment (MaHTAS) HPV vaccine - an update
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Ozanimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 706
2021     National Institute for Health and Care Excellence (NICE) Transvaginal laser therapy for urogenital atrophy. NICE interventional procedures guidance 697
2021     European Network for Health Technology Assessment (EUnetHTA) Nafamostat for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) COVID-19 - interventions and health related factors that prevent infection or minimise progression to severe disease
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111]
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer. NICE technology appraisal guidance 707
2021     National Institute for Health and Care Excellence (NICE) Permanent His-bundle pacemaker implantation for treating heart failure. NICE interventional procedures guidance 694
2021     European Network for Health Technology Assessment (EUnetHTA) Solnatide for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Review of processes in use to inform the expansion of newborn bloodspot screening programmes
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Addendum to Commission A20-106]
2021     National Institute for Health and Care Excellence (NICE) Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis. NICE technology appraisal guidance 708
2021     National Institute for Health and Care Excellence (NICE) Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma. NICE interventional procedures guidance 692
2021     European Network for Health Technology Assessment (EUnetHTA) Anakinra for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Economic burden of antimicrobial resistance: an analysis of additional costs associated with resistant infections
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 709
2021     National Institute for Health and Care Excellence (NICE) Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults. NICE interventional procedures guidance 693
2021     European Network for Health Technology Assessment (EUnetHTA) APN01 for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating atypical haemolytic uraemic syndrome. NICE technology appraisal guidance 710
2021     National Institute for Health and Care Excellence (NICE) Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. NICE interventional procedures guidance 691
2021     European Network for Health Technology Assessment (EUnetHTA) Darunavir for the treatment of COVID-19
2021     Norwegian Institute of Public Health (NIPH) [Medpor polyethylene implant in reconstructive ear surgery in patients with microtia: rapid health technology assessment]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Enzalutamide for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 712
2021     National Institute for Health and Care Excellence (NICE) Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids. NICE interventional procedures guidance 689
2021     European Network for Health Technology Assessment (EUnetHTA) Favipiravir for the treatment of COVID-19
2021     Norwegian Institute of Public Health (NIPH) [Description and quality assessment of guidelines for tonsillectomy in patients with recurrent tonsillitis: mapping review]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irreversible electroporation in chronic bronchitis - Addendum to commission H20-03]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Antithrombotic treatments following heart valve replacement surgeries]
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 713
2021     National Institute for Health and Care Excellence (NICE) Extracorporeal whole liver perfusion for acute liver failure. NICE interventional procedures guidance 690
2021     European Network for Health Technology Assessment (EUnetHTA) Sarilumab for the treatment of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Second Addendum to Commission A20-104]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19]
2021     National Institute for Health and Care Excellence (NICE) Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 714
2021     National Institute for Health and Care Excellence (NICE) Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury. NICE interventional procedures guidance 687
2021     European Network for Health Technology Assessment (EUnetHTA) Interferon (IFN) and Novaferon (NOVA) for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Identification of demand models for estimating the quantities of personal protective equipment (PPE) required for optimal patient care in the context of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia) - Second Addendum to Commission A20-103]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Validity of thermometers for peripheral temperature measurement]
2021     National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. NICE technology appraisal guidance 715
2021     National Institute for Health and Care Excellence (NICE) Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. NICE interventional procedures guidance 688
2021     European Network for Health Technology Assessment (EUnetHTA) Gimsilumab for the treatment of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Drug-coated balloon dilatation catheter for transurethral treatment of urethral strictures - Addendum to commission H20-02]
2021     National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 716
2021     National Institute for Health and Care Excellence (NICE) Self-expanding implant insertion into the intersphincteric space for faecal incontinence. NICE interventional procedures guidance 685
2021     European Network for Health Technology Assessment (EUnetHTA) Canakinumab for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Rapid antigen testing for screening or surveillance of asymptomatic individuals to limit transmission of SARS-CoV-2
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia) - Addendum to Commission A20-103]
2021     National Institute for Health and Care Excellence (NICE) Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 717
2021     National Institute for Health and Care Excellence (NICE) Minimally invasive radical hysterectomy for early stage cervical cancer. NICE interventional procedures guidance 686
2021     European Network for Health Technology Assessment (EUnetHTA) Casirivimab and imdevimab (REGN-COV2) for the treatment of COVID-19
2021     Health Information and Quality Authority (HIQA) Reduction of the minimum age for the application of mask wearing requirements and recommendations – updated advice
2021     Canary Health Service [Effectiveness of measures to close or restrict occupancy in ceremonial and worship places in the context of the SARS-CoV-2 pandemic]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Addendum to Commission A20-104]